Signaling Pathways and Immune-Checkpoint Regulation in Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 3168
Special Issue Editor
Special Issue Information
Dear Colleagues,
The more we discover how cancer is interrelated with the whole human system, the more cancer management tends to become holistic. The immune system plays a pivotal role in cancer development and progression. Since the very first approval of a checkpoint inhibitor for cancer management (i.e., ipilimumab, an anti-CTLA4 antibody approved in 2011 for the treatment of metastatic melanoma), research in this field has made tremendous progress, and immunotherapy has increasingly become a pivotal weapon in clinics, improving the outcomes of tumors which only a few years back were unimaginably difficult (or very unlikely) to effectively treat.
Nevertheless, the success of this innovative approach comes with challenges which still need to be surmounted. These include the existence of a certain percentage of non-responder patients, the possibility of developing detrimental immune-related adverse events, as well as the potential rise of resistance to therapy and tumor relapse.
Seeking better knowledge of signaling pathways involved in immune-checkpoint regulation might help to overcome arising issues and improve the overall benefits of this revolutionary interventional approach. For example, the latest milestone research has revealed how interindividual variations in intestinal microbiome may play a pivotal role in the observed heterogeneity of the response to immune-checkpoint inhibitors.
This Special Issue, entitled “Signaling Pathways and Immune-Checkpoint Regulation in Cancers”, welcomes contributions in the form of original research articles or reviews, aiming to shed light and explore all the novel molecular players involved in the inhibition of both known (e.g., CTLA-4, PD-1/PD-L1) and emerging (e.g., CD47, TIGIT, KIR-L, LAG-3, TIM-3, etc.) immune checkpoints.
Dr. Silvia Vivarelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
